Actelion Is Building 50-Rep U.S. Sales Force For Tezosentan, TNKase
Executive Summary
The Swiss pharmaceutical company Actelion plans to have a 50-rep sales force in the U.S. by the middle of 2001 to support the launch of Genentech's TNKase and its own tezosentan.